Nurr1 as a Genetic Target for Treating Levodopa-induced Dyskinesias (LIDs) in Parkinson's Disease
Patients afflicted with Parkinson’s disease often develop severely debilitating movement disorders as side effects from currently available treatment options. Researchers at MSU propose to use a new gene therapy approach that will both reduce these side effects and prolong the effectiveness of treatment by targeted gene silencing.
Description of Technology
L-Dopa induced dyskinesia (LID) is a side effect of prolonged chronic use of L-Dopa medication. A hyper-expression of Nurr1 protein in affected brain areas might underlie these side effects. Local injection of vectors encoding target genes in affected striatum can directly prevent the hyper-expression allowing for potentially improved fine-tuned response for motor control.
- Improved quality of life for Parkinson’s patients
- Improved and prolonged benefit for movement disorders
- Treatment of LID in patients with Parkinson’s disease
- Potentially useful in the treatment of other movement disorders
Click Here to View a Poster on this Technology Presented by the Inventors
Click Here to View a Second Poster on this Technology Presented by the Inventors
US patent application published, no. 20170198295; foreign patent application published, no. WO2015188077A1
Licensing Rights Available
Full licensing rights available
Inventors: Fredric Manfredsson, Kathy Steece-Collier, Jack Lipton, Timothy Collier, Nicholas Kanaan, Caryl Sortwell
Tech ID: TEC2014-0099
Alternative contact due to temporary leave:
Nina (Isi) Davis, Technology Marketing Manager, email: email@example.com, phone (direct): (517)884-1829.
For Information, Contact:
Michigan State University